Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine.
J Clin Psychiatry August 21, 2024 DOI: 10.4088/jcp.24com15504 via PubMed
Summary
AI-generated from the abstractThe article examines the problem of functional unblinding in pivotal clinical trials of psychedelic medicines, where participants and clinicians can often guess treatment assignment due to the drugs' subjective effects, potentially biasing results. It argues that this unblinding threatens the integrity of placebo-controlled designs and discusses implications for the future of psychedelic research and regulation. The authors suggest that alternative trial designs, such as active comparators or novel blinding strategies, may be needed to produce credible evidence for regulatory approval.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Key finding | Functional unblinding poses a significant methodological challenge to placebo-controlled psychedelic trials, requiring alternative trial designs to ensure valid evidence. |
Abstract
Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine.